Press release -
Global Biobetters Market: Development of Biopharmaceuticals to Create Newer Versions of Expired Patent Biologicals to Create Opportunities
MarketResearchReports.Biz presents this most up-to-date research on “ Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings "
The report examines biobetters in key markets, focusing on the statistics of the industry. The report, titled ‘Biobetters In Key Markets - Opportunities For Biotechnology Companies To Sustain Innovation With Low Risk And High Value Offerings,’ is available for sale on the official website of MarketResearchReports.biz.
Biobetters are therapies that have improved qualities over their originators. The report examines the most recent biobetter launches and have come to the conclusion that they generate more revenues than their corresponding originator therapies. As such, the market for biobetters is expected to grow. Since biobetters provide significant improvements to reference drugs, they are anticipated to be in high demand in the coming years. Branded pharmaceutical companies, biotech, and other large generic companies, established in biosimilars market are increasingly turning to biobetters. It is estimated that biobetters will emerge as a lucrative alternative to biosimilars, and drive the market towards growth.
On the other hand, the rising cost of existing and expensive biopharmaceuticals as against the low priced and easily available biosimilars are expected to impact the global biobetters therapeutics market. However, market players such as Novo Nordisk, Roche, and Merck & Co are developing biopharmaceuticals so as to create newer versions of expired patent biologicals. These new biopharmaceuticals are faster and have reduced side effects.
The report reviews the role played by biosimilars and how it has led to the development of biobetters. It presents the rationale behind biobetters with factors leading to a growing interest in their development. In addition to this, the report concisely outlines how companies are helping biobetters evolve and the areas of their potential use.
View Press Release Report at : http://www.marketresearchreports.biz/pressrelease/2569
The first section of the report comprises the introduction of biobetters. The next section gives a market overview, which includes the competition from branded products, impact and promising targets of biobetter therapies, and a comparison of biobetter and biosimilar therapies. The next section assesses the technological landscape of the biobetters therapeutics market. Key opportunities and challenges in the market are also analyzed.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/125694
The next section of the report outlines the pipeline of the key drug biobetter classes and analyzes the most promising drugs and key pipeline products. The detailed analysis of regulatory bodies for biobetters in the EU, Japan, the U.S., China, India, and Australia has been given in the study. In addition to this, the report analyzes key companies operating in the biobetters therapeutics market such as Amgen, Celgene, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, and Amylin. It also benchmarks and profiles the top five companies based on sales value. Strategic consolidations among key players been included. As such, the report proves to be useful not only new players but also for those established.
- biobetters market
- market research reports